GlobeNewswire
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
📈
AI Sentiment
Highly Positive
8/10
- Home
- LXEO
as of 12-05-2025 3:46pm EST
$9.38
+$0.29
+3.14%
Stocks Nasdaq
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Chart Type:
Time Range:
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 663.5M | IPO Year: | 2023 |
| Target Price: | $18.22 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.45 - $10.38 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered LXEO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 72.50%
72.50%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Lexeo Therapeutics Inc. (LXEO)
Adler Eric
Sell
Chief Medical Officer
LXEO Nov 18, 2025
Avg Cost/Share
$9.27
Shares
615
Total Value
$5,701.05
Owned After
72,646
SEC Form 4
Robertson Jenny
Sell
Chief Legal Officer
LXEO Nov 18, 2025
Avg Cost/Share
$9.27
Shares
549
Total Value
$5,089.23
Owned After
68,381
SEC Form 4
Townsend Richard Nolan
Sell
Chief Executive Officer
LXEO Nov 18, 2025
Avg Cost/Share
$9.27
Shares
1,127
Total Value
$10,447.29
Owned After
240,991
SEC Form 4
See Tai Sandi
Sell
Chief Development Officer
LXEO Nov 18, 2025
Avg Cost/Share
$9.27
Shares
386
Total Value
$3,578.22
Owned After
65,476
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Adler Eric | LXEO | Chief Medical Officer | Nov 18, 2025 | Sell | $9.27 | 615 | $5,701.05 | 72,646 | |
| Robertson Jenny | LXEO | Chief Legal Officer | Nov 18, 2025 | Sell | $9.27 | 549 | $5,089.23 | 68,381 | |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Nov 18, 2025 | Sell | $9.27 | 1,127 | $10,447.29 | 240,991 | |
| See Tai Sandi | LXEO | Chief Development Officer | Nov 18, 2025 | Sell | $9.27 | 386 | $3,578.22 | 65,476 |
Latest Lexeo Therapeutics Inc. News
LXEO Breaking Stock News: Dive into LXEO Ticker-Specific Updates for Smart Investing
Compare LXEO vs Leading Stocks
See how LXEO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LXEO Lexeo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.